Chagas Disease Therapeutics Market, By Drug type (Nifurtimox and Benznidazole), By Treatment type (Symptomatic treatment and Antiparasitic treatment), By Type (Acute chagas disease and Chronic chagas disease), By Distribution channel (Hospital pharmacies, Retail pharmacies and Online pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Chagas disease is a parasitic infection caused by Trypanosoma cruzi, which is found in the faeces of the triatomine bug, popularly known as the kissing bug because it bites humans on the face as they sleep. It creates a sudden and severe illness that lasts for a long time. It is transmitted from mother to foetus during pregnancy, through blood transfusions, and occasionally through organ transplantation. Fever, headache, and local swelling at the bite site, as well as enlarged lymph nodes, are early indications of Chagas disease. Purplish inflammation of an eyelid or skin lesion is the first obvious sign in around half of those bitten by the triatominae bug. Muscle discomfort, difficulty breathing, enlarged lymph glands, edoema, headache, pallor, and stomach ness chest pain are among the other symptoms. Chagas disease is a rare infectious disease that can be found all over the world.

The Chagas Disease Therapeutics Market accounted for US$ x.x billion in 2020 and is estimated to be US$ x.x billion by 2030 and is anticipated to register a CAGR of x.x%.

Impact of Covid-19 pandemic on market

The global COVID-19 epidemic is wreaking havoc on disadvantaged areas already struggling with neglected tropical diseases. COVID-19 has the potential to have three major effects on the global economy: directly impacting production and demand, causing supply chain and market disruption, and having a financial impact on businesses and financial markets. COVID-19's possible impact on the heart necessitates special consideration for the nearly one million people globally with chronic Chagas cardiomyopathy; also, the pandemic influences treatment for persons with acute or chronic indeterminate Chagas disease. The consequences of co-infection with SARS-CoV-2 and Trypanosoma cruzi, the etiological agent of Chagas disease, are discussed.

Rising initiatives by government bodies

In April 2018, the international humanitarian organization Médecins Sans Frontières/Doctors Without Borders (MSF) initiated a campaign. The campaign aims to raise public awareness about Chagas disease, which is still widespread in Latin American countries and affects around 6 million people worldwide. The World Health Organization (WHO) initiated a programme in 2007 to raise Chagas disease treatment rates and eradicate the disease. Bayer HealthCare, which makes the drug nifurtimox, which is used to treat Chagas disease, contributed to this WHO initiative. In 2007, Bayer and WHO agreed to fund the programme by delivering 2.5 million free pills to WHO for the treatment of an anticipated 30,000 patients over a five-year period (from 2007 to 2011). The WHO and Bayer agreement was extended in 2011. From 2012 through 2017, Bayer is expected to distribute 5 million complimentary tablets, according to the deal. Such activities are projected to propel market expansion in the near future.

Growth in business operations by emerging and small sized players

The factors driving the growth of the Chagas disease treatment market during the forecast period include an increase in R&D activities for the development of novel Chagas disease treatments and approval for new products, a rise in the prevalence of Chagas disease due to unsanitary conditions, and an increase in the Chagas disease population. Several competitors in the chagas disease therapy market have been boosting their research efforts in recent years. The development of novel therapeutic options for chagas disease is the primary motivation for this move. Furthermore, a number of vendors have received authorisation for the launch of new items. The market for chagas disease therapy is growing as a result of these causes.

The global chagas disease treatment market is segmented based on drug type, treatment type, type, distribution channel, and region.

On the basis of Drug type, the global chagas disease therapeutics market is segmented into Nifurtimox and Benznidazole. Based on Treatment type, the target market is segmented into Symptomatic treatment and Antiparasitic treatment. On the basis of Type, the target market is segmented into chronic chagas disease and acute chagas disease. On the basis of Distribution channel, the target market is segmented into Hospital pharmacies, Retail pharmacies and Online pharmacies.

Regional Insights:

On region the Global Chagas Disease Therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Latin America is one of the key regions where the market for chagas disease treatment is predicted to grow rapidly. The rising number of chagas disease patients is one of the main factors driving the region's market growth. Aside from that, the chagas disease treatment industry is predicted to benefit from increased awareness of the disease among the region's major population.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global chagas disease therapeutics  market report based on drug type, treatment type, type, distribution channel, and region.

Global Chagas Disease Therapeutics Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global chagas disease therapeutics market includes F. Hoffmann-La Roche Ltd., KaloBios Pharmaceuticals, Inc., Johnson & Johnson, ELEA SACIF Laboratory, Bayer AG, Humanigen, Inc, Savant HWP, Inc, Eisai Co., Ltd, Oblita Therapeutics, GlaxoSmithKline plc, Collaborations Pharmaceuticals, Inc, Astellas Pharma Inc, Sanofi, Pfizer Inc, Epichem Pty Ltd, DAIICHI SANKYO COMPANY, LIMITED, Insud Pharma group, Novartis AG, Kancera AB, AstraZeneca, Maprimed S.A. and others.

Key Issues Addressed

• F. Hoffmann-La Roche Ltd*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• KaloBios Pharmaceuticals Inc.
• Johnson & Johnson
• ELEA SACIF Laboratory
• Bayer AG
• Humanigen, Inc.
• Savant HWP Inc.
• Eisai Co., Ltd
• Oblita Therapeutics
• GlaxoSmithKline plc

“*” marked represents similar segmentation in other categories in the respective section.